Sino Biopharmaceutical (OTCMKTS:SBMFF) Trading Down 8% - Here's What Happened

Key Points

• Sino Biopharmaceutical shares dropped by 8% during trading on Tuesday, with the stock last trading at $0.91.
• The stock's trading volume was approximately 1,000 shares, marking a 62% decline from the average daily volume of 2,650 shares.
• Sino Biopharmaceutical operates as a research and development pharmaceutical conglomerate in China, offering a range of medications including oncology and liver disease treatments.

Sino Biopharmaceutical (OTCMKTS:SBMFF - )'s share price dropped 8% during trading on Tuesday . The stock traded as low as $0.91 and last traded at $0.91. Approximately 1,000 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 2,650 shares. The stock had previously closed at $0.99.

Sino Biopharmaceutical Stock Down 8.0%

The company has a 50 day moving average price of $1.05 and a 200 day moving average price of $0.76.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.